Lantheus (NASDAQ:LNTH) Given New $127.00 Price Target at Truist Financial

Lantheus (NASDAQ:LNTH - Get Free Report) had its price target upped by investment analysts at Truist Financial from $120.00 to $127.00 in a report issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the medical equipment provider's stock. Truist Financial's price target suggests a potential upside of 33.88% from the company's current price.

A number of other brokerages have also recently weighed in on LNTH. StockNews.com cut Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. The Goldman Sachs Group initiated coverage on shares of Lantheus in a research note on Wednesday, December 18th. They set a "buy" rating and a $143.00 price target on the stock. Finally, JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 price objective on shares of Lantheus in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $132.86.

Lantheus Stock Performance

Lantheus stock traded up $1.04 during mid-day trading on Thursday, hitting $94.86. 1,336,679 shares of the company traded hands, compared to its average volume of 899,600. Lantheus has a one year low of $56.44 and a one year high of $126.89. The stock has a market cap of $6.60 billion, a price-to-earnings ratio of 15.78 and a beta of 0.44. The stock has a fifty day moving average price of $89.89 and a 200-day moving average price of $96.73.

Remove Ads

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million for the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Sell-side analysts predict that Lantheus will post 6.01 EPS for the current year.

Insider Buying and Selling

In other Lantheus news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the sale, the director now owns 33,207 shares of the company's stock, valued at $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC increased its position in Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider's stock valued at $184,798,000 after purchasing an additional 32,551 shares during the period. Moloney Securities Asset Management LLC bought a new stake in shares of Lantheus during the 3rd quarter valued at about $1,066,000. Massachusetts Financial Services Co. MA purchased a new position in shares of Lantheus during the third quarter valued at about $25,955,000. Van ECK Associates Corp raised its stake in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock worth $6,469,000 after buying an additional 21,604 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider's stock worth $1,041,000 after buying an additional 3,772 shares during the period. Institutional investors own 99.06% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.